Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Icariin soft capsules added to sintilimab + bevacizumab for unresectable hepatocellular carcinoma
ChiCTR2300077606Phase 4Recruiting
- Sponsor
- Third Affiliated Hospital of Naval Medical University
- Start
- Nov 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of icariin, sintilimab and bevacizumab in hepatocellular carcinoma (HCC), sponsored by Third Affiliated Hospital of Naval Medical University. Primary endpoints: Overall survival and Progression-free survival. Started Nov 2023; status: recruiting.
02
Drugs
icariinsintilimabbevacizumab
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2300077606.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300077606.